A novel potential biomarker for renal cell carcinoma (RCC) tumours has been discovered. Levels of a protein called progesterone receptor membrane component 1 (PGRMC1) have been shown to be raised in a number of different human cancers; however, the roles of PGRMC1 in renal cancer are not clear and merit further study. In the current study, PGRMC1 levels were found to be increased nearly 4-fold in RCC tumours compared to normal tissue and nearly twice compared to tissue from a healthy person. Raised PGRMC1 level was related to the degree of tumour malignancy and overall survival of RCC patients. The researchers suggest that PGRMC1 is a novel potential biomarker and therapeutic target for RCC.
Potential novel biomarker for kidney cancer
23 Jan 2017
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec